Copenhagen, Capital Region of Denmark, Denmark
Project Vice President at Novo Nordisk. Responsible for driving projects from research to phase 1. 15+ years experience in drug research and development. Proven ability to drive execution, translate science into drug development programs, and manage large-scale global programs with quality and precision resulting in several new MoAs IND/CTA submissions. • Profound understanding of the pharmaceutical value chain, including R&D, CMC/product supply, non-clinical, clinical, regulatory and commercialization. • Experience with cardiometabolic & rare diseases • Have a global mindset with the ability to lead strategically and collaboratively across teams
Project Vice President in Research & Development. Responsible for driving global drug projects from idea to clinical phase 1 development
Managing a portfolio of Novo Nordisk R&D alliances with universities, biotech and pharmaceutical companies
My job is to identify strategic partnering opportunities and create partnerships with universities and biotech companies in order to access medical innovations originating in Europe but for global markets - allowing Ferring to optimize its pipeline and to increase its probability of success in in-licensing new product candidates. My responsible includes: • Identify and evaluate opportunities in Europe for global asset in-licensing in the Ferring core therapeutic areas • Establish and cultivate relationships with innovative leaders, which are expected to lead to partnerships, licensing agreement or acquisition agreement • Conduct in-depth landscape analyses in the therapeutic areas through networking and on-site visits • Participate in academic and technical conferences to promote Ferring as the partner of the choice • Build strong network with relevant internal departments to ensure an in-depth overview of technology and expertise • Build business cases for the targeted innovation licensing or acquisition • Build appropriate deal structure and through due diligence obtain management support for the investments • Align search priorities to reflect existing therapeutic and technology strategies • Lead and coordinate scouting activities with global stakeholders
CEO & co-founder of Curasight. Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Department of Nuclear Medicine, Rigshospitalet. Part of the company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace
Project: PET imaging of uPAR – translational studies Explore the full potential for translating a first-in-class uPAR PET imaging ligand into the clinic. Responsible of both pre-clinical tests in advanced human cancer mouse models, toxicological assessment and regulatory approval for first-in-man studies.
Project: Development and in vivo characterization of a number of peptide-based uPAR PET imaging ligands. Studies conducted within radiochemistry, HPLC, cell-based assays, Biacore, ELISA, in vivo human cancer xenograft models and microPET/CT imaging. PhD thesis, including 5 original publications, handed in Oct. 2012 and successfully defended Marts 22. 2013, at the University of Copenhagen. Part of the studies was performed at Stanford University.